Date: 2012-09-17
Type of information: Licensing agreement
Compound: induced pluripotent stem (iPS) cell patent portfolio
Company: EMD Millipore (USA), the Life Science Division of Merck KGaA (Germany) - iPS Academia (Japan)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism:
Disease:
Details: EMD Millipore, the Life Science division of Merck KGaA, and iPS Academia Japan, have announced a global licensing agreement for AJ’s induced pluripotent stem (iPS) cell patent portfolio. The non-exclusive agreement provides EMD Millipore the opportunity to continue to develop and ultimately commercialize iPS cells for research applications. Under the agreement, EMD Millipore will continue to offer its STEMCCA™ reprogramming kits, which provide a highly efficient, reproducible method for creating iPS cells. The iPS cell patent portfolio is a result of work by Professor Shinya Yamanaka, MD, PhD, Center for iPS Cell Research and Application at Kyoto University, Japan. Terms of the agreement are not disclosed.
Financial terms:
Latest news:
